First CyberKnife in Belgium to be Installed at Leading University Hospital

Academic Center to Establish Full Set of Offerings for Cancer Patients in Belgium

SUNNYVALE, California, December 14 - Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of
radiosurgery, announced today that the first CyberKnife(R) Robotic
Radiosurgery System in Belgium will be installed at the University Hospital
of Liege.

The University Hospital in Liege, a 1,000-bed hospital, is one of the
largest hospitals in Euregio, a cross-country region of 18 million
inhabitants.

"With a full range of cancer treatments, University Hospital of Liege is
delivering on its promise to offer comprehensive, state-of-the-art cancer
care to patients across Belgium," said Professor Philippe Coucke, Head of the
Radiation Oncology Department, University Hospital of Liege. "Because of its
accuracy and non-invasive nature, the CyberKnife System can offer an
alternative to patients who may not be able to tolerate other cancer
treatments or who have medically inoperable tumors."

According to the International Agency for Research on Cancer, the total
number of new cases of cancer in Europe has increased by approximately
300,000 since 2004. With an estimated 3.2 million new cases and 1.7 million
deaths each year, cancer remains an important public health issue in Europe.
The situation described by the Belgian Cancer Registry is similar, with
57,185 new cancer cases reported in 2005.

"We are extremely excited to see the benefits of whole body radiosurgery
expand into Belgium," said Frederic Sottilini, General Manager, Accuray EIMEA
(Europe, India, Middle East and Africa). "This purchase paves the way for
greater patient access to CyberKnife radiosurgery, thereby providing patients
an additional treatment option that can improve their quality of life."

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment. This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body
stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an improved
quality of life and a non-surgical treatment option for those diagnosed with
cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery
System, which extends the benefits of radiosurgery to include extracranial
tumors, including those in the spine, lung, prostate, liver and pancreas. To
date, the CyberKnife System has been used to treat more than 70,000 patients
worldwide and currently 180 Systems have been installed in leading hospitals
in the Americas, Europe and Asia. For more information, please visit
www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry. Except for the historical information contained herein, the
matters set forth in this press release, including statements relating to
treatment options and particular patient treatments are forward-looking
statements within the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Forward-looking statements speak
only as of the date the statements are made and are based on information
available at the time those statements are made and/or management's good
faith belief as of that time with respect to future events. You should not
put undue reliance on any forward-looking statements. Important factors that
could cause actual performance and results to differ materially from the
forward-looking statements we make include: market acceptance of products;
competing products, the combination of our products with complementary
technology; and other risks detailed from time to time under the heading
"Risk Factors" in our report on Form 10-K for our 2009 fiscal year, our Form
10-Q filed on November 6, 2009 and our other filings with the Securities and
Exchange Commission. The Company's actual results of operations may differ
significantly from those contemplated by such forward-looking statements as a
result of these and other factors. We assume no obligation to update
forward-looking statements to reflect actual performance or results, changes
in assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities laws.

Stephanie Tomei, Senior Manager, Marketing Communications, +1-408-789-4234, stomei at accuray.com, Sancie Nakarat, Manager, EU Marketing, +33-155-232-028, snakarat at accuray.com, both of Accuray Incorporated